Tenofovir Disoproxil Fumarate-Associated Renal Dysfunction Among Adult People Living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: A Comparative Retrospective Cohort Study

References

• Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate. Clin Pharmacokinet. 2004;43(9):595–612. doi:10.2165/00003088-200443090-00003
   PubMed Web of Science ®Google Scholar
• Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non‐nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral‐naïve individuals. Cochrane Database Syst Rev. 2010;10.
   Google Scholar
• Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773–780. doi:10.1053/j.ajkd.2011.01.022
   PubMed Web of Science ®Google Scholar
• Salome T, Kasamba I, Mayanja BN, et al. The effect of tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis. AIDS Res Ther. 2016;13(1):28. doi:10.1186/s12981-016-0113-z
   PubMed Web of Science ®Google Scholar
• Mayanja BN, Kasamba I, Levin J, et al. Cohort profile: the complications of long-term antiretroviral therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther. 2017;14(1):26. doi:10.1186/s12981-017-0154-y
   Web of Science ®Google Scholar
• Fritzsche C, Rudolph J, Huenten-Kirsch B, et al. Effect of tenofovor diproxil fumarate on renal function and urinalysis abnormalities in HIV-infected cameroonian adults. Am J Trop Med Hyg. 2017;97(5):1445–1450. doi:10.4269/ajtmh.17-0060
   Web of Science ®Google Scholar
• Koh HM, Suresh K. Tenofovir-induced nephrotoxicity: a retrospective cohort study. Med J Malaysia. 2016;71(6):308–312.
   PubMedGoogle Scholar
• Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6(7):e22661. doi:10.1371/journal.pone.0022661
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23(6):689–696. doi:10.1097/QAD.0b013e3283262a64
   PubMed Web of Science ®Google Scholar
• Mizushima D, Tanuma J, Kanaya F, et al. WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in vietnamese HIV-infected patients. PLoS One. 2013;8(11):e79885. doi:10.1371/journal.pone.0079885
   PubMed Web of Science ®Google Scholar
• Laprise C, Baril J-G, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis. 2012;56(4):567–575.
   Web of Science ®Google Scholar
• Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract. 2012;25(5):552–559. doi:10.1177/0897190012442718
   Google Scholar
• Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70(9):1029–1040. doi:10.1007/s00228-014-1712-z
   PubMed Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496–505. doi:10.1086/655681
   PubMed Web of Science ®Google Scholar
• Ojeh BV, Abah IO, Ugoagwu P, Agaba PA, Agbaji OO, Gyang SS. Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients. Germs. 2018;8(2):67. doi:10.18683/germs.2018.1133
   PubMedGoogle Scholar
• Olivier D. The Effect of Tenofovir on Renal Function and Immunological Response in HIV-Positive Patients in Lesotho. Bloemfontein: Central University of Technology, Free State; 2013.
   Google Scholar
• Yazie TS, Orjino TA, Degu WA. Reduced kidney function in tenofovir disoproxil fumarate based regimen and associated factors: a hospital based prospective observational study in Ethiopian patients. Int J Nephrol. 2019;2019:1–9. doi:10.1155/2019/9172607
   Web of Science ®Google Scholar
• De Waal R, Cohen K, Fox MP, et al. Changes in estimated glomerular filtration rate over time in South African HIV‐1‐infected patients receiving tenofovir: a retrospective cohort study. J Int AIDS Soc. 2017;20(1):21317. doi:10.7448/IAS.20.01/21317
   Web of Science ®Google Scholar
• Agbaji OO, Abah IO, Ebonyi AO, et al. Long term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy is associated with renal impairment in an African cohort of HIV-infected adults. J Int Assoc Provid AIDS Care. 2019;18:2325958218821963. doi:10.1177/2325958218821963
   Google Scholar
• Silver SA, Chertow GM. The economic consequences of acute kidney injury. Nephron. 2017;137(4):297–301. doi:10.1159/000475607
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D: a: d Studya. J Infect Dis. 2013;207(9):1359–1369. doi:10.1093/infdis/jit043
   PubMed Web of Science ®Google Scholar
• Lapadula G, Bernasconi DP, Casari S, et al. Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment. PLoS One. 2016;11(9):e0162320. doi:10.1371/journal.pone.0162320
   PubMed Web of Science ®Google Scholar
• Organization WH. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization; 2016.
   Google Scholar
• Frehiwot N, Mizan K, Seble M, Fethia K, Tekalign M, Zelalem T. National Guidelines for Comprehensive HIV Prevention, Care and Treatment. Addis Ababa: Ministry of Health; 2014.
   Google Scholar
• Vidyasagar V RNC, Ankam S Dr, Naidu R, Das SK, Drr. T. Tenofovir induced nephrotoxicity – a case report. Eur J Pharm Med Res. 2016;3(3):381–382.
   Google Scholar
• Suzuki S, Nishijima T, Kawasaki Y, et al. Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1–infected treatment-naïve Asian patients: results from 12-year observational cohort. AIDS Patient Care STDS. 2017;31(3):105–112. doi:10.1089/apc.2016.0286
   PubMed Web of Science ®Google Scholar
• Ahmed E, Diro E, Hailu W, Muhie OA. Assessment of renal dysfunction and associated factors among patients on Tenofovir based antiretroviral treatment at Gondar University Hospital, North West Ethiopia: retrospective institution based cross sectional study. J AIDS HIV Res. 2020;12(2):34–44. doi:10.5897/JAHR2019.0498
   Google Scholar
• Health UDo, Services H. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDSinfo; 2018. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines. Accessed April 27, 2021.
   Google Scholar
• Daniel WW, Cross CL. Biostatistics: A Foundation for Analysis in the Health Sciences. Wiley; 1995.
   Google Scholar
• Cleves M. An Introduction to Survival Analysis Using Stata. Stata Press; 2008.
   Google Scholar
• Ryan TP. Sample Size Determination and Power. John Wiley & Sons; 2013.
   Google Scholar
• Obiebi IP, Nwannadi EA. Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: prospects for early detection of presymptomatic nephrotoxicity. Kidney Res Clin Pract. 2018;37(3):230. doi:10.23876/j.krcp.2018.37.3.230
   Web of Science ®Google Scholar
• Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96–e138.
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5–14.
   Web of Science ®Google Scholar
• Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622. doi:10.1053/j.ajkd.2010.02.337
   PubMed Web of Science ®Google Scholar
• Tanuma J, Jiamsakul A, Makane A, et al. Renal dysfunction during tenofovir use in a regional cohort of HIV-infected individuals in the Asia-Pacific. PLoS One. 2016;11(8):e0161562. doi:10.1371/journal.pone.0161562
   Web of Science ®Google Scholar
• Kyaw NTT, Harries AD, Chinnakali P, et al. Low incidence of renal dysfunction among HIV-infected patients on a tenofovir-based first line antiretroviral treatment regimen in Myanmar. PLoS One. 2015;10(8):e0135188. doi:10.1371/journal.pone.0135188
   PubMed Web of Science ®Google Scholar
• Calcagno A, de Requena DG, Simiele M, et al. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother. 2013;57(4):1840–1843. doi:10.1128/AAC.02434-12
   PubMed Web of Science ®Google Scholar
• Shamu T, Wellington M, Pascoe M, Gwanzura L, Ndhlovu C. Incidence of nephropathy in HIV infected patients receiving highly active antiretroviral therapy at Newlands Clinic: a retrospective study. World J AIDS. 2015;5(02):113. doi:10.4236/wja.2015.52014
   Google Scholar
• Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: part I. Definition, disease stages, evaluation. Am Fam Physician. 2004;70(5):869–876.
   Web of Science ®Google Scholar
• Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107(37):647. doi:10.3238/arztebl.2010.0647
   PubMed Web of Science ®Google Scholar
• Lee JE, Lee S, Song SH, Kwak IS, Lee SH. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea. Korean J Intern Med. 2019;34(2):409. doi:10.3904/kjim.2016.418
   Web of Science ®Google Scholar
• Mulenga L, Musonda P, Mwango A, et al. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia. Clin Infect Dis. 2014;58(10):1473–1480. doi:10.1093/cid/ciu117
   PubMed Web of Science ®Google Scholar
• Nishijima T, Gatanaga H, Komatsu H, et al. Renal function declines more in tenofovir-than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection. PLoS One. 2012;7(1):e29977. doi:10.1371/journal.pone.0029977
   PubMed Web of Science ®Google Scholar
• Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23–e32. doi:10.1016/S2352-3018(15)00211-8
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26(15):1907. doi:10.1097/QAD.0b013e328357f5ed
   PubMed Web of Science ®Google Scholar
• Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23(15):1971. doi:10.1097/QAD.0b013e32832c96e9
   PubMed Web of Science ®Google Scholar
• Tanaka H, Arai M, Tomoda Y, Wada T, Yago K, Satoh M. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients. J Pharm Pharm Sci. 2013;16(3):405–413. doi:10.18433/J32P5C
   Web of Science ®Google Scholar
• Santiago P, Grinsztejn B, Friedman RK, et al. Screening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income country. PLoS One. 2014;9(4):e93748. doi:10.1371/journal.pone.0093748
   Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102–108. doi:10.1086/524061
   PubMed Web of Science ®Google Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, Phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43–52. doi:10.1016/S1473-3099(15)00348-5
   PubMed Web of Science ®Google Scholar
• Pablo Tebas M, Amanda Clarke M, Laurent Cotte M, William Short M, Andrew Cheng M. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a Single-Arm, Multicenter, Open-Label Phase 3 Study. 2016.
   Google Scholar